Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Myelofibrosis, Post ET Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

NCT00931762
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
Interventions
Panobinostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Sep 30, 2026, 5:47 AM EDT
Recruiting Phase 3 Interventional

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Interventions
Navtemadlin, Navtemadlin placebo, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 30, 2026, 5:47 AM EDT
Not listed Phase 1Phase 2 Interventional

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

NCT04640532
View directory record Official record
Conditions
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Interventions
KRT-232, TL-895
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Whittier, California • Lake City, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 30, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

NCT03373877
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
PU-H71, Ruxolitinib
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
New Haven, Connecticut • New Orleans, Louisiana • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for Myelofibrosis Patients

NCT00946270
View directory record Official record
Conditions
Polycythemia Vera, Thrombocythemia
Interventions
CC-4047, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 30, 2026, 5:47 AM EDT
Not listed Phase 1Phase 2 Interventional

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

NCT01298934
View directory record Official record
Conditions
Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
Interventions
LBH589
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

NCT01149681
View directory record Official record
Conditions
Myelofibrosis
Interventions
APLIDIN (plitidepsin)
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

NCT01732445
View directory record Official record
Conditions
Anemia, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
ruxolitinib phosphate, danazol, quality-of-life assessment, questionnaire administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Scottsdale, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 30, 2026, 5:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509
View directory record Official record
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Interventions
TL-895, Ruxolitinib
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 30, 2026, 5:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

NCT06327100
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
Interventions
Ruxolitinib, Tasquinimod
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
CYT387
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Sep 30, 2026, 5:47 AM EDT
Terminated Phase 2 Interventional Results available

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

NCT02730884
View directory record Official record
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Sep 30, 2026, 5:47 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

NCT00630994
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Interventions
Dacogen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 1 Interventional

MPN-RC 118 AVID200 in Myelofibrosis

NCT03895112
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF, Post PV MF
Interventions
AVID200
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Sep 30, 2026, 5:47 AM EDT
Not listed Phase 1 Interventional

A Safety and Tolerability Study of Jaktinib

NCT05279001
View directory record Official record
Conditions
Myelofibrosis
Interventions
Jaktinib Hydrochloride Tablet
Drug
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 2 Interventional Results available

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161
View directory record Official record
Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 30, 2026, 5:47 AM EDT
Terminated Phase 1 Interventional

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

NCT03935555
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
PU-H71
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Larkspur, California • Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 30, 2026, 5:47 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

NCT04629508
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocythemia
Interventions
itacitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
New Orleans, Louisiana • Bethesda, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 30, 2026, 5:47 AM EDT